Trends in hormonal management of prostate cancer: A population-based study in Ontario

Medical Care

Volumn 39, Issue 4, 2001, Pages 384-396

  Bondy, Susan J ^a   Iscoe, Neill A ^a   Rothwell, Deanna M ^c   Gort, Elaine H ^a   Fleshner, Neil E ^b   Paszat, Lawrence F ^a   Browman, George P ^c  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c G 106 ^*

Author keywords

Antineoplastic agents; Hormonal; Orchidectomy; Physician's practice patterns; Practice guidelines; Prostatic neoplasms

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ARTICLE; CANADA; CLINICAL PRACTICE; HUMAN; MALE; PROSTATE TUMOR; STATISTICAL MODEL; STATISTICS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; LOGISTIC MODELS; MALE; ONTARIO; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS;

EID: 0035319494     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200104000-00009     Document Type: Article

References (58)

1. Klotz L, To T, Iscoe N, Naylor CD. Variations in surgical services over time and by site of residence: orchidectomy as a treatment for prostate cancer. In: Naylor CD, Anderson GM, Goel V, editors. Patterns of Health Care in Ontario. Ottawa: Canadian Medical Association, 1994: 111-114.
2. To T, Iscoe N, Klotz L, Naylor CD. Orchidectomy and hormonal therapy of prostate cancer. Can J Urol 1995;2:109-115.
3. To T, Klotz LH, Iscoe NA, Tran M. Variations in selected surgical procedures and medical diagnoses by year and region: Orchidectomy. In: Goel V, Williams J, Anderson G, Blackstein-Hirsch P, Fooks C, Naylor C, es. Patterns of Health Care in Ontario. The ICES Practice Atlas. Toronto: Institute for Clinical Evaluative Sciences in Ontario, 1996: 130-134.
4. Mahler C, Verhelst J, Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 1998;34:405-417.
5. Aronson N, Seidenfeld J, Samson D, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. Agency for Health Care and Policy Research (Agency for Healthcare Research and Quality) AHCPR Publication No. 99-E0012. 1999. Rockville, MD, Agency for Health Care Policy and Research, United States Department of Health and Human Services. Evidence Report/Technology Assessment No. 4.
6. Austenfeld MS, Thompson IM, Middelton RG, et al. Meta-analysis of the literature: guideline development for prostate cancer treatment. J Urol 1994;152:1866-1869.
7. Hamdy FC, Johnson MI, Robson CN. Prostate Cancer. In: Mundy AR, Fitzpatrick JM, Neal DE, George NJR, editors. Scientifc Basis of Urology. Oxford: Isis Medical Media 1999:355-373.
8. Blandy J, Fowler C. Prostate - neoplasms. In: Osney Mead, Arnette Blackwell SA, Blackwell Wissenschafts-Verlag GMbH, editors. Urology. Oxford: Blackwell Science 1996:405-426.
9. Prostate Cancer Practice Guidelines Panel Members. NCCN Prostate Cancer Practice Guidelines. Oncology 1996;10(suppl 11):265-288.
10. van Tinteren H, Dalesio O. Systematic overview (meta-analysis) of all randomized trials of treatment of prostate cancer. Cancer 1993;72(suppl 12):3847-3850.
11. Rago R. Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer. Cancer Control: Journal of the Moffitt Cancer Center 1998;5:513-521.
12. Griffiths K. Is there a best castration? Cancer 1993;72(suppl 12):3807-3809.
13. Goethuys H, Baert L, Van Poppel H, et al. Treatment of metastatic carcinoma of the prostate. Am J Clin Oncol 1997;20:40-45.
14. Soloway MS. Combined androgen blockade: an optimal therapy for minimally advanced prostate cancer? Br J Urol 1998;81:87-94.
15. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. Urology 1989;33(suppl 5):57-62.
16. Trachtenberg J. Progress in complete androgen blockade. Eur Urol 1997;31(suppl 3):8-10.
17. Boccon-Gibod L. Are non-steroidal antiandrogens appropriate as monotherapy in advanced prostate cancer? Eur Urol 1998;33:159-164.
18. Labrie F, Dupont A, Belanger A. New approach in the treatment of prostatic cancer: complete instead of partial withdrawal of androgens. Prostate 1983;4:579-594.
19. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-1042.
20. de Voogt HJ, Studer U, Schroder FH, et al. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998;33:152-158.
21. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center Eur Urol 1998;33:144-151.
22. Bono AV, DiSilverio F, Robustelli DC, et al. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group Urologia International 1998;60(suppl 1):18-24.
23. Dijkman GA, Janknegt RA, De Reijke TM, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group J Urol 1997;158:160-163.
24. Zalcberg JR, Raghaven D, Marshall V, et al. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate-an Australian multicentre trial. Br J Urol 1996;77:865-869.
25. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-82.
26. Boccardo F, Pace M, Rubagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group European Journal of Cancer 1993;29A:1088-1093.
27. Iversen P, Rasmussen F, Klarskov P, et al. Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 1993;72(suppl 12)3851-3854.
28. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
29. Denis L. Role of maximal androgen blockade in advanced prostate cancer. Prostate 1994;5(suppl):17-22.
30. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-269.
31. Caubet J, Tosteson T, Dong E, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997;49:71-78.
32. Bennett CL, Tosteson TD, Ernstoff MS, et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published reandomized controlled trials and 4,128 patients using flutamide. Prostate Cancer Prostatic Dis 1999;2:4-8.
33. To T, Iscoe N, Klotz L, Naylor C. Patterns of use of specific drugs in the elderly: prostate cancer. In: Naylor C, Anderson G, Goel V, editors. Patterns of Health Care in Ontario. The ICES Practice Atlas. Toronto: Institute for Clinical Evaluative Sciences in Ontario; 1994: 307-317.
34. Hillner BE, McLeod DG, Crawford ED, et al. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995;45:633-640.
35. Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998;33:134-143.
36. Robson M, Dawson N. How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 1996;10:727-747.
37. Kirk D. Combined androgen blockade: an optimal therapy for minimally advanced prostate cancer? Br J Urol 1998;81:94-95.
38. Denis L. European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996;Urology 1998:51(suppl 5A):50-57.
39. Small EJ. Prostate cancer, incidence, management and outcomes. Drugs Aging 1998;13:71-81.
40. Studer UE, Mills RD. Arguments against the long-term use of combined androgen blockade. Eur Urol 1998;34 (suppl 3):29-32.
41. Wajsman Z. Arguments for the long-term use of combined androgen blockade. Eur Urol 1998;34 (suppl 3):25-28.
42. National Comprehensive Cancer Network, American Cancer Society, Inc. Prostate Cancer Treatment Guidelines for Patients: Version I, June 1999:99-40 M-No.9402-HCP. 1999.
43. Schroder FH. Antiandrogens as monotherapy for prostate cancer. Eur Urol 1998;34 (suppl 3):12-17.
44. Schellhammer PF, Lynch DF. Are monotherapy options reasonable for T3 prostate cancer? Semin Urol Oncol 1997;15:207-214.
45. Tyrrell CJ, Denis L, Newling D, et al. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer, an overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group Eur Urol 1998;33:39-53.
46. Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998;34:61-72.
47. Gillis M, Welbank L, Bergeron D, et al ed. Compendium of Pharmaceuticals and Specialties. 44th Ed. Ottawa, Ontario: Canadian Pharmacists Association; 1999.
48. Soloway MS, Schellhammer PF, Smith JAJ, et al. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. J Urol 1995;154:2110-2114.
49. Clarke EA, Marrett LD, Kreiger N. Twenty Years of Cancer Incidence, 1964-1983. Toronto, Ontario: Ontario Cancer Treatment and Research Foundation; 1987.
50. Clarke EA, Marrett LD, Kreiger N. Appendix 3(c). Cancer registration in Ontario: a computer approach. In: Jensen OM, Parkin D, MacLennan R, Muir C, Skeet R, eds. Cancer Registration: Principles and Methods. Lyon: International Agency for Research on Cancer; 1991:246-257.
51. National Cancer Institute of Canada. Canadian Cancer Statistics 2000: Toronto; 2000.
52. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995;154:1642-1645.
53. Fleshner NE, Trachtenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol 1993;24 (suppl 2):106-112.
54. Ziada AM, Crawford ED. Advanced prostate cancer. Prostate Cancer and Prostatic Diseases 1999;2:21-26.
55. Iversen P, Tveter K, Varenhorst E. Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand J Urol Nephrol 1996;30:93-98.
56. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51:389-396.
57. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-456.
58. Gleave M, Bruchovsky N, Goldenberg SL, et al. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol 1998;34 (suppl 3):37-41.